Weight Watchers International, Inc. Stock News

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or “the Company”) will release its results for the third quarter 2024 before market open on Wednesday, November 6, 2024.

WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares soaring nearly 47%.

Shares of WW International Inc (WW, Financial) soared by 43.09% today due to the company's strategic move to expand its clinical weight management services. This expansion includes the introduction of compounded semaglutide, which offers a cost-effective and accessible alternative to popular medications like Ozempic and Wegovy, particularly during the current supply shortages.

WW International (WW, Financial) experienced a significant stock price increase, soaring 20.7% to $1.40. Early trading saw the stock rise as much as 46.5%.

WW International (WW, Financial), a provider of weight loss solutions, experienced a significant stock movement with an initial surge of over 46.5%, which later narrowed to around a 25% increase, reaching $1.45. This follows a nearly 47% rise in the previous trading session.

Shares of WW International (WW), better known as WeightWatchers, jumped nearly 25% Tuesday when the dieting services company announced it is offering a copycat version of blockbuster weight-loss drugs.

“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Executive Tara Comonte in prepared remarks.

WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its weight-management programs.